The majority of the AMPs currently undergoing clinical trials exert their antimicrobial effects by damaging the bacterial membrane . Since bacterial membrane structures tend to be more conserved than proteins, membrane-targeting AMPs offer a promising strategy to bypass the resistance problem that plagues many conventional antibiotics. The compositional differences and thus the different properties of Gram-negative and Gram-positive bacterial membranes are reflected in the structural diversity of membrane-active AMPs.